top of page
Search

ViVerita Therapeutics Announces Research Collaboration with Boehringer Ingelheim to Accelerate Discovery of Novel Cancer Targets

  • uelling
  • May 7
  • 1 min read

ViVerita Therapeutics today announced a strategic research collaboration with Boehringer Ingelheim aimed at accelerating the discovery and validation of novel therapeutic targets. Under the terms of this collaboration, ViVerita will leverage its industry-leading in vivo CRISPR-based discovery platform to evaluate a curated set of putative targets identified by Boehringer Ingelheim, assessing their functions under physiologically relevant conditions.





 
 
 
bottom of page